Branch² Intelligence
Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?
Key takeaway
Dr Reddy's delays semaglutide supply due to API quality issue, shares -9%.
- Step 1Dr Reddy's delays semaglutide supply due to API quality issue.
- Step 2Brokerages cut target prices and EPS estimates, triggering a 9% share price drop.
- Step 3Competitors accelerate their own semaglutide launches, capturing market share Dr Reddy's expected to hold.
Source: IN:Economic Times
This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.